文献速递癫痫神经重症与神经感染

疑似或确诊急性症状性癫痫发作后的抗癫痫药物使用与结局

Antiseizure Medication Use and Outcomes After Suspected or Confirmed Acute Symptomatic Seizures.
PubMed 文献 · JAMA Neurol · 2024-09-23

这项多中心队列研究纳入1172例无癫痫的住院成人,在连续脑电图监测后分析抗癫痫药物使用因素及与结局的关联;病因和脑电图表现与用药相关,而用药与出院及3个月功能结局无显著关联。

要点

  • 临床急性症状性发作、脑电图发作和癫痫样异常患者的住院用药率分别为82%、96%和64%。
  • 急性与进行性脑损伤、入住神经科/神经外科或神经ICU与用药几率升高独立相关。
  • 抗癫痫药物与出院或3个月功能结局无显著关联。

核心结论

  • 本研究提示病因和脑电图发现与急性症状性发作及癫痫样异常的ASM治疗相关,ASM治疗与功能结局无显著关联,需开展比较有效性研究以明确哪些患者可能获益及最佳治疗时长。

研究设计与样本

  • 多中心队列研究,于2021年7月1日至9月30日在美国5个中心开展,筛查1717例后纳入1172例无癫痫的住院成人,均在目击或疑似急性症状性发作后接受连续脑电图监测。

主要发现

  • 1172例患者中,285例(24%)有临床急性症状性发作,107例(9%)有脑电图发作,364例(31%)有癫痫样异常,532例(45%)接受ASM治疗。
  • 出院时存活922例,其中288例(31%)被处方ASM;临床发作、脑电图发作和癫痫样异常患者的住院ASM治疗率分别为82%(233/285)、96%(103/107)和64%(233/364),出院处方率分别为69%(169/246)、95%(61/64)和48%(128/267)。
  • 多变量分析显示,急性和进行性脑损伤与住院ASM治疗几率升高独立相关(OR分别为3.86 [95%CI, 2.06-7.32]和8.37 [95%CI, 3.48-20.80]),也与出院处方几率升高相关(OR分别为2.26 [95%CI, 1.04-4.98]和10.10 [95%CI, 3.94-27.00])。
  • 入住神经科或神经外科(OR, 2.56 [95%CI, 1.08-6.18])或神经重症监护室(OR, 7.98 [95%CI, 3.49-19.00])与治疗几率升高相关;急性症状性发作和癫痫样异常与ASM治疗几率升高显著相关(OR分别为14.30 [95%CI, 8.52-24.90]和2.30 [95%CI, 1.47-3.61]),也与出院处方几率升高相关(OR分别为12.60 [95%CI, 7.37-22.00]和1.72 [95%CI, 1.00-2.97])。
  • ASM治疗与出院时结局(OR, 0.96 [95%CI, 0.61-1.52])或初始表现后3个月结局(OR, 1.26 [95%CI, 0.78-2.04])无显著关联;出院后3个月存活且有完整数据的623例中,30例(5%)出院后出现癫痫发作,187例(30%)正在使用ASM,202例(32%)发生全因再入院。

临床怎么用

  • 原文结论指出,本研究提示病因和脑电图发现与ASM治疗相关,ASM治疗与功能结局无显著关联;作者认为需开展比较有效性研究以识别可能从ASM获益的患者并确定最佳治疗时长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antiseizure medications (ASMs) are frequently prescribed for acute symptomatic seizures and epileptiform abnormalities (EAs; eg, periodic or rhythmic patterns). There are limited data on factors associated with ASM use and their association with outcomes. OBJECTIVES: To determine factors associated with ASM use in patients with confirmed or suspected acute symptomatic seizures undergoing continuous electroencephalography, and to explore the association of ASMs with outcomes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study was performed between July 1 and September 30, 2021, at 5 US centers of the Post Acute Symptomatic Seizure Investigation and Outcomes Network. After screening 1717 patients, the study included 1172 hospitalized adults without epilepsy who underwent continuous electroencephalography after witnessed or suspected acute symptomatic seizures. Data analysis was performed from November 14, 2023, to February 2, 2024. EXPOSURE: ASM treatment (inpatient ASM continuation ≥48 hours). MAIN OUTCOMES AND MEASURES: Factors associated with (1) ASM treatment, (2) discharge ASM prescription, and (3) discharge and 3-month Glasgow Outcome Scale score of 4 or 5 were ascertained. RESULTS: A total of 1172 patients (median [IQR] age, 64 [52-75] years; 528 [45%] female) were included. Among them, 285 (24%) had clinical acute symptomatic seizures, 107 (9%) had electrographic seizures, and 364 (31%) had EAs; 532 (45%) received ASM treatment. Among 922 patients alive at discharge, 288 (31%) were prescribed ASMs. The respective frequencies of inpatient ASM treatment and discharge prescription were 82% (233 of 285) and 69% (169 of 246) for patients with clinical acute symptomatic seizures, 96% (103 of 107) and 95% (61 of 64) for electrographic seizures, and 64% (233 of 364) and 48% (128 of 267) for EAs. On multivariable analysis, acute and progressive brain injuries were independently associated with increased odds of inpatient ASM treatment (odds ratio [OR], 3.86 [95% CI, 2.06-7.32] and 8.37 [95% CI, 3.48-20.80], respectively) and discharge prescription (OR, 2.26 [95% CI, 1.04-4.98] and 10.10 [95% CI, 3.94-27.00], respectively). Admission to the neurology or neurosurgery service (OR, 2.56 [95% CI, 1.08-6.18]) or to the neurological intensive care unit (OR, 7.98 [95% CI, 3.49-19.00]) was associated with increased odds of treatment. Acute symptomatic seizures and EAs were significantly associated with increased odds of ASM treatment (OR, 14.30 [95% CI, 8.52-24.90] and 2.30 [95% CI, 1.47-3.61], respectively) and discharge prescription (OR, 12.60 [95% CI, 7.37-22.00] and 1.72 [95% CI, 1.00-2.97], respectively). ASM treatment was not associated with outcomes at discharge (OR, 0.96 [95% CI, 0.61-1.52]) or at 3 months after initial presentation (OR, 1.26 [95% CI, 0.78-2.04]). Among 623 patients alive and with complete data at 3 months after discharge, 30 (5%) had postdischarge seizures, 187 (30%) were receiving ASMs, and 202 (32%) had all-cause readmissions. CONCLUSIONS AND RELEVANCE: This study suggests that etiology and electrographic findings are associated with ASM treatment for acute symptomatic seizures and EAs; ASM treatment was not associated with functional outcomes. Comparative effectiveness studies are indicated to identify which patients may benefit from ASMs and to determine the optimal treatment duration.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Zafar SF, Sivaraju A, Rubinos C, et al. Antiseizure Medication Use and Outcomes After Suspected or Confirmed Acute Symptomatic Seizures. JAMA Neurol. 2024. PMID: 39312247. doi:10.1001/jamaneurol.2024.3189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。